市場調查報告書

全球體外診斷市場機會分析/行業預測(2020-2027):按產品和服務,技術,用途,最終用戶

In Vitro Diagnostics Market by Product & Service, Technique, Application, and End User : Global Opportunity Analysis and Industry Forecast, 2020-2027

出版商 Allied Market Research 商品編碼 951341
出版日期 內容資訊 英文 381 Pages
商品交期: 2-3個工作天內
價格
全球體外診斷市場機會分析/行業預測(2020-2027):按產品和服務,技術,用途,最終用戶 In Vitro Diagnostics Market by Product & Service, Technique, Application, and End User : Global Opportunity Analysis and Industry Forecast, 2020-2027
出版日期: 2020年06月01日內容資訊: 英文 381 Pages
簡介

2019年,全球體外診斷(IVD)市場價值為671.11億美元,預計到2020年至2027年,複合年增長率為4.8%,達到910.93億美元。導致體外診斷市場增長的主要因素是由於慢性病和傳染病的發病率增加,體外診斷檢測的數量迅速增加。此外,易患免疫疾病的老年人口增加是市場增長的另一個主要驅動力。另外,越來越多地使用個性化藥物來治療各種慢性疾病,例如癌症,也幫助市場增長。此外,與體外診斷產品,技術,軟件和服務相關的技術進步也幫助市場增長。但是,嚴格的政府法規和不利的醫療保健補償政策預計會限制體外診斷市場的增長。另一方面,在預測期內,新興經濟體的高增長率可能會為體外診斷市場的主要參與者提供機會。

該報告調查了全球體外診斷市場,並提供了市場概況和動態,按細分市場/區域進行的市場規模分析和預測以及關鍵的公司概況。

第1章簡介

第2章執行摘要

第3章市場概述

  • 市場定義和範圍
  • 主要發現
    • 主要投資口袋
  • 主要成功策略
  • 主要公司的定位
  • 波特的五力分析
  • 市場動態
    • 促進要因
      • 增加慢性病和傳染病的發病率
      • IVD技術進步
      • 越來越多地採用體外診斷測試
      • 政府在醫療保健方面的支出增加
      • 個性化醫療方法日益普及
    • 抑制因子
      • 不清楚的醫療費用報銷政策
      • 嚴格的監管政策
    • 市場機會
      • 潛在的外包機會
      • 融合新技術
    • 影響分析
  • 分析COVID-19對體外診斷市場的影響

第4章按產品和服務分類的體外診斷市場

  • 概述
    • 市場規模和預測
  • 試劑
    • 主要市場趨勢/增長因素/機會
    • 市場規模和地區預測
    • 國家市場分析
  • 設備
  • 軟件服務

第5章按技術分類的體外診斷市場

  • 概述
    • 市場規模和預測
  • 免疫診斷
    • 市場規模和預測:按類型
      • □聯免疫吸附測定(ELISA)
      • 快速檢查
      • □聯免疫斑點(ELISPOT)
      • 放射免疫分析(RIA)
      • 蛋白質印跡
    • 市場規模和地區預測
    • 國家市場分析
  • 血液學
    • 市場規模和地區預測
    • 國家市場份額分析
  • 分子診斷
    • 市場規模和預測:按類型
      • 聚合鏈反應(PCR)
      • 等溫核酸擴增技術(INAAT)
      • 雜交
      • DNA診斷
      • 微陣列
      • 其他
    • 市場規模和地區預測
    • 國家市場份額分析
  • 組織診斷
    • 市場規模和地區預測
    • 國家市場份額分析
  • 臨床化學
    • 市場規模和預測:按類型
      • 基本生化檢驗
      • 肝臟面板
      • 腎臟概況
      • 脂質分佈
      • 甲狀腺功能面板
      • 電解質板
      • 特殊化學品
    • 市場規模和地區預測
    • 國家市場佔有率分析
  • 其他
    • 市場規模和地區預測
    • 國家市場佔有率分析

第6章體外診斷市場的應用

  • 概述
    • 市場規模和預測
  • 傳染病
    • 市場規模和地區預測
    • 國家市場份額分析
  • 癌症
  • 心臟疾病
  • 免疫系統疾病
  • 腎臟疾病
  • 胃腸道疾病
  • 其他

第7章最終用戶體外診斷市場

  • 概述
    • 市場規模和預測
  • 獨立實驗室
    • 市場規模和地區預測
    • 國家市場佔有率分析
  • 醫院
  • 大學/醫學院
  • 即時檢驗
  • 其他

第8章按地區劃分的體外診斷市場

  • 概述
    • 市場規模和預測
  • 北美
    • 主要市場趨勢/增長因素/機會
    • 市場規模和國家預測
      • 美國
      • 加拿大
      • 墨西哥
    • 按產品/服務劃分的市場規模和預測
    • 市場規模和技術預測
    • 市場規模和按應用預測
    • 最終用戶的市場規模和預測
  • 歐洲
    • 主要市場趨勢/增長因素/機會
    • 市場規模和國家預測
      • 德國
      • 法國
      • 英國
      • 意大利
      • 西班牙
      • 其他歐洲
    • 按產品/服務劃分的市場規模和預測
    • 市場規模和技術預測
    • 市場規模和按應用預測
    • 最終用戶的市場規模和預測
  • 亞太地區
    • 主要市場趨勢/增長因素/機會
    • 市場規模和國家預測
      • 印度
      • 中國
      • 日本
      • 澳大利亞
      • 韓國
      • 其他亞太地區
    • 按產品/服務劃分的市場規模和預測
    • 市場規模和技術預測
    • 市場規模和按應用預測
    • 最終用戶的市場規模和預測
  • 拉丁美洲/中東/非洲
    • 主要市場趨勢/增長因素/機會
    • 市場規模和國家預測
      • 巴西
      • 沙特阿拉伯
      • 南非
      • 其他LAMEA
    • 按產品/服務劃分的市場規模和預測
    • 市場規模和技術預測
    • 市場規模和按應用預測
    • 最終用戶的市場規模和預測

第9章公司簡介

  • ABBOTT LABORATORIES
  • BECTON, DICKINSON AND COMPANY
  • BIOMERIEUX SA
  • BIO-RAD LABORATORIES, INC.
  • DANAHER CORPORATION (BECKMAN COULTER, INC.)
  • F. HOFFMANN-LA ROCHE AG.
  • QIAGEN N.V.
  • SIEMENS AG (SIEMENS HEALTHINEERS)
  • SYSMEX CORPORATION
  • THERMO FISHER SCIENTIFIC, INC.
目錄
Product Code: A00245

Title:
In Vitro Diagnostics Market by Product & Service (Reagents, Instruments, and Software & Services), Technique (Immunodiagnostics, Hematology, Molecular Diagnostics, Tissue Diagnostics, Clinical Chemistry, and Others), Application (Infectious Diseases, Cancer, Cardiac Diseases, Immune System Disorders, Nephrological Diseases, Gastrointestinal Diseases, and Others), and End User (Standalone Laboratory, Hospitals, Academic & Medical Schools, Point of Care, and Others): Global Opportunity Analysis and Industry Forecast, 2020-2027.

The global in vitro diagnostics market (IVD) was valued at $67,111 million in 2019, and is projected to reach $91,093 million at a CAGR of 4.8% from 2020 to 2027.

In vitro diagnostics (IVD) are defined as medical devices and reagents which are used to examine specimens such as blood, urine, stool, tissues, and other body fluids, which are derived from human body to detect diseases, conditions, and infections. The tests can be performed in stand-alone laboratory, hospital-based laboratory, and point-of-care centers. Some significant technologies incorporated in in vitro diagnostics include polymerase chain reaction (PCR), microarray techniques, sequencing technology, and mass spectrometry, which are used for test sample preparation. Moreover, other techniques that are used to perform in vitro diagnosis involve clinical chemistry, tissue diagnostics, immunodiagnostics, hematology, and others. For instance, in clinical chemistry various tests are performed in laboratory such as liver panel test, lipid profile, thyroid function test, and others.

Furthermore, a thyroid function test is performed by collecting blood from a patient, which is then tested to check the level of thyroid stimulating hormone (TSH) in blood. Similarly, others such as polymerase chain reaction (PCR) are used to detect the presence of infectious diseases such as HIV, hepatitis, and others. In addition, constant innovations related to IVD products, service designs, and technology have encouraged doctors and researchers to shift their focus from traditional diagnostic methods to personalized medicines. For instance, some products that are used to perform various in vitro diagnostic tests using various technologies involve real time PCR detection systems, immunoassay systems, and others.

The major factor that contributes to the growth of the in vitro diagnostic market include surge in number of in vitro diagnostic tests, which is attributable to rise in incidences of chronic and infectious diseases. Furthermore, growth in geriatric population, which is prone to immunological disorders is another major factor that boosts the growth of the market. Moreover, rise in use of personalized medicines in treatment of various chronic diseases such as cancer also fuels the growth of the market. In addition, increase in technological advancements associated with in vitro diagnostic products, technologies, and software & services boosts the market growth. However, stringent government regulations and unfavorable reimbursement policies are anticipated to restrict the growth of the in vitro diagnostics market. On the contrary, high growth rate exhibited by developing economies present lucrative opportunities for key players in the in vitro diagnostics market during the forecast period.

The report segments the market across into product & service, technique, application, end user, and region. On the basis of product & service, the market is segmented into reagents, instruments, and services & software. On the basis of technique, it is categorized into immunodiagnostics, hematology, molecular diagnostics, tissue diagnostics, clinical chemistry, and others. In addition, the immunodiagnostics segment is further divided into types such as enzyme-linked immunosorbent assay (ELISA), rapid tests, enzyme-linked immunospot (ELISPOT), radioimmunoassay (RIA), and western blot. Moreover, the ELSIA segment is further divided into chemiluminescence immunoassay (CLIA), fluorescence immunoassay (FIA), and colorimetric immunoassay (CI). Similarly, the molecular diagnostics segment is divided into polymerize chain reaction (PCR), isothermal nucleic acid amplification technology (INAAT), hybridization, DNA diagnostics, microarray, and others.

The clinical chemistry segment is also further divided basic metabolic panel, liver panel, lipid profile, thyroid function panel, electrolyte panel, specialty chemicals, and others.

On the basis of application, the market segmented into infectious diseases, cancer, cardiac diseases, immune system disorders, nephrological diseases, gastrointestinal diseases, and others. On the basis of end user, it is categorized into standalone laboratories, hospitals, academics & medical schools, point-of-care, and others. Region wise, the market is analyzed across North America (the U.S., Canada, and Mexico), Europe (Germany, France, the UK, Italy, Spain, and rest of Europe), Asia-Pacific (Japan, China, Australia, India, South Korea, and rest of Asia-Pacific), and LAMEA (Brazil, South Africa, Saudi Arabia, and rest of LAMEA).

The major players in the in vitro diagnostics market are Abbott Laboratories, Becton, Dickinson and Company, bioMerieux SA, Bio-Rad Laboratories, Inc., Danaher Corporation (Beckman Coulter, Inc.), F. Hoffmann-La Roche AG, Siemens AG, QIAGEN N.V., Sysmex Corporation, and Thermo Fisher Scientific, Inc.

KEY BENEFITS FOR STAKEHOLDERS

  • This report entails a detailed quantitative analysis along with the current global negative pressure wound therapy devices market trends from 2019 to 2027 to identify the prevailing opportunities along with the strategic assessments.
  • The market size and estimations are based on a comprehensive analysis of key developments in the industry.
  • A qualitative analysis based on innovative products facilitates strategic business planning.
  • The development strategies adopted by the key market players are enlisted to understand the competitive scenario of the market

Key Market Segments

  • By Product & Service
  • Reagents
  • Instruments
  • Software and Services
  • By Technique
  • Immunodiagnostics
  • § Enzyme-Linked Immunosorbent Assay (ELISA)
  • Chemiluminescence Immunoassay (CLIA)
  • Fluorescence immunoassay (FIA)
  • Colorimetric Immunoassay (CI)
  • § Rapid Tests
  • § Enzyme-Linked ImmunoSpot (ELISPOT)
  • § Radioimmunoassay (RIA)
  • § Western Blot
  • Hematology
  • Molecular Diagnostics
  • § Polymerize Chain Reaction (PCR)
  • § Isothermal Nucleic Acid Amplification Technology (INAAT)
  • § Hybridization
  • § DNA diagnostics
  • § Microarray
  • § Others
  • Tissue Diagnostics
  • Clinical Chemistry
  • § Basic Metabolic Panel
  • § Liver Panel
  • § Lipid Profile
  • § Thyroid Function Panel
  • § Electrolyte Panel
  • § Specialty Chemicals
  • Others
  • By Application
  • Infectious Diseases
  • Cancer
  • Cardiac Diseases
  • Immune System Disorders
  • Nephrological Diseases
  • Gastrointestinal Diseases
  • Others
  • By End User
  • Standalone Laboratories
  • Hospitals
  • Academic & Medical Schools
  • Point-of-Care
  • Others
  • By Region
  • North America
  • § U.S.
  • § Canada
  • § Mexico
  • Europe
  • § Germany
  • § France
  • § UK
  • § Italy
  • § Spain
  • § Rest of Europe
  • Asia-Pacific
  • § Japan
  • § China
  • § India
  • § Australia
  • § South Korea
  • § Rest of Asia-Pacific
  • LAMEA
  • § Brazil
  • § Saudi Arabia
  • § South Africa
  • § Rest of LAMEA

List of key players profiled in the report:

  • Abbott Laboratories
  • Becton, Dickinson and Company
  • bioMerieux SA
  • Bio-Rad Laboratories, Inc.
  • Danaher Corporation (Beckman Coulter, Inc.)
  • F. Hoffmann-La Roche AG
  • Siemens AG
  • QIAGEN N.V.
  • Sysmex Corporation
  • Thermo Fisher Scientific, Inc.
  • LIST OF OTHER PLAYERS IN THE VALUE CHAIN (These players are not profiled in the report. The same will be included on request)
  • DiaSorin
  • Johnson & Johnson

TABLE OF CONTENTS

CHAPTER 1:INTRODUCTION

  • 1.1.Report description
  • 1.2.Key benefits for stakeholders
  • 1.3.Key market segments
    • 1.3.1.List of key players profiled in the report
  • 1.4.Research methodology
    • 1.4.1.Secondary research
    • 1.4.2.Primary research
    • 1.4.3.Analyst tools and models

CHAPTER 2:EXECUTIVE SUMMARY

  • 2.1.Key findings of the study
  • 2.2.CXO perspective

CHAPTER 3:MARKET OVERVIEW

  • 3.1.Market definition and scope
  • 3.2.Key findings
    • 3.2.1.Top investment pockets
  • 3.3.Top winning strategies, 2019
  • 3.4.Top player positioning, 2019
  • 3.5.Porters five forces analysis
  • 3.6.Market dynamics
    • 3.6.1.Drivers
      • 3.6.1.1.Increase in incidences of chronic and infectious diseases
      • 3.6.1.2.Technological advancements in IVD
      • 3.6.1.3.Rise in adoption of in vitro diagnostic testing
      • 3.6.1.4.Increase in government expenditures on healthcare
      • 3.6.1.5.Increase in popularity of personalized medicine approach
    • 3.6.2.Restraint
      • 3.6.2.1.Unclear reimbursement policies
      • 3.6.2.2.Stringent regulatory policies
    • 3.6.3.Opportunities
      • 3.6.3.1.Potential opportunities for outsourcing
      • 3.6.3.2.Convergence of new technologies
    • 3.6.4.Impact Analysis
  • 3.7.COVID-19 Impact Analysis for In Vitro Diagnostics Market

CHAPTER 4:IN VITRO DIAGNOSTICS MARKET, BY PRODUCT & SERVICE

  • 4.1.Overview
    • 4.1.1.Market size and forecast
  • 4.2.Reagents
    • 4.2.1.Key market trends, growth factors, and opportunities
    • 4.2.2.Market size and forecast, by region
    • 4.2.3.Market analysis, by country
  • 4.3.Instruments
    • 4.3.1.Key market trends, growth factors, and opportunities
    • 4.3.2.Market size and forecast, by region
    • 4.3.3.Market analysis, by country
  • 4.4.Software & Services
    • 4.4.1.Market size and forecast, by region
    • 4.4.2.Market analysis, by country

CHAPTER 5:IN VITRO DIAGNOSTICS MARKET, BY TECHNIQUE

  • 5.1.Overview
    • 5.1.1.Market size and forecast
  • 5.2.Immunodiagnostics
    • 5.2.1.Market size and forecast, by type
      • 5.2.1.1.Enzyme-linked immunosorbent assay (ELISA)
      • 5.2.1.1.1.Market size and forecast, by type
      • 5.2.1.1.2.Chemiluminescence Immunoassay (CLIA)
      • 5.2.1.1.2.1.Market size and forecast
      • 5.2.1.1.3.Fluoresence immunoassay (FIA)
      • 5.2.1.1.3.1.Market size and forecast
      • 5.2.1.1.4.Colorimetric Immunoassay (CI)
      • 5.2.1.1.4.1.Market size and forecast
      • 5.2.1.2.Rapid Tests
      • 5.2.1.2.1.Market size and forecast
      • 5.2.1.3.Enzyme-linked immunospot (ELISPOT)
      • 5.2.1.3.1.Market size and forecast
      • 5.2.1.4.Radioimmunoassay (RIA)
      • 5.2.1.4.1.Market size and forecast
      • 5.2.1.5.Western blot
      • 5.2.1.5.1.Market size and forecast
    • 5.2.2.Market size and forecast, by region
    • 5.2.3.Market analysis, by country
  • 5.3.Hematology
    • 5.3.1.Market size and forecast, by region
    • 5.3.2.Market share analysis, by country
  • 5.4.Molecular diagnostics
    • 5.4.1.Market size and forecast, by type
      • 5.4.1.1.Polymerize chain reaction (PCR)
      • 5.4.1.1.1.Market size and forecast
      • 5.4.1.2.Isothermal Nucleic acid amplification technology (INAAT)
      • 5.4.1.2.1.Market size and forecast
      • 5.4.1.3.Hybridization
      • 5.4.1.3.1.Market size and forecast
      • 5.4.1.4.DNA diagnostics
      • 5.4.1.4.1.Market size and forecast
      • 5.4.1.5.Microarray
      • 5.4.1.5.1.Market size and forecast
      • 5.4.1.6.Others
      • 5.4.1.6.1.Market size and forecast
    • 5.4.2.Market size and forecast, by region
    • 5.4.3.Market share analysis, by country
  • 5.5.Tissue diagnostics
    • 5.5.1.Market size and forecast, by region
    • 5.5.2.Market share analysis, by country
  • 5.6.Clinical chemistry
    • 5.6.1.Market size and forecast, by type
      • 5.6.1.1.Basic metabolic panel
      • 5.6.1.1.1.Market size and forecast
      • 5.6.1.2.Liver panel
      • 5.6.1.2.1.Market size and forecast
      • 5.6.1.3.Renal profile
      • 5.6.1.3.1.Market size and forecast
      • 5.6.1.4.Lipid profile
      • 5.6.1.4.1.Market size and forecast
      • 5.6.1.5.Thyroid function panel
      • 5.6.1.5.1.Market size and forecast
      • 5.6.1.6.Electrolyte panel
      • 5.6.1.6.1.Market size and forecast
      • 5.6.1.7.Specialty chemicals
      • 5.6.1.7.1.Market size and forecast
    • 5.6.2.Market size and forecast, by region
    • 5.6.3.Market share analysis, by country
  • 5.7.Others
    • 5.7.1.Market size and forecast, by region
    • 5.7.2.Market share analysis, by country

CHAPTER 6:IN-VITRO DIAGNOSTICS MARKET, BY APPLICATION

  • 6.1.Overview
    • 6.1.1.Market size and forecast
  • 6.2.Infectious Diseases
    • 6.2.1.Market size and forecast, by region
    • 6.2.2.Market share analysis, by country
  • 6.3.Cancer
    • 6.3.1.Market size and forecast, by region
    • 6.3.2.Market share analysis, by country
  • 6.4.Cardiac diseases
    • 6.4.1.Market size and forecast, by region
    • 6.4.2.Market share analysis, by country
  • 6.5.Immune system disorders
    • 6.5.1.Market size and forecast, by region
    • 6.5.2.Market share analysis, by country
  • 6.6.Nephrological diseases
    • 6.6.1.Market size and forecast, by region
    • 6.6.2.Market share analysis, by country
  • 6.7.Gastrointestinal diseases
    • 6.7.1.Market size and forecast, by region
    • 6.7.2.Market share analysis, by country
  • 6.8.Others
    • 6.8.1.Market size and forecast, by region
    • 6.8.2.Market share analysis, by country

CHAPTER 7:IN VITRO DIAGNOSTICS MARKET, BY END USER

  • 7.1.Overview
    • 7.1.1.Market size and forecast
  • 7.2.Standalone Laboratories
    • 7.2.1.Market size and forecast, by region
    • 7.2.2.Market share analysis, by country
  • 7.3.Hospitals
    • 7.3.1.Market size and forecast, by region
    • 7.3.2.Market share analysis, by country
  • 7.4.Academic and medical schools
    • 7.4.1.Market size and forecast, by region
    • 7.4.2.Market share analysis, by country
  • 7.5.Point-of-care testing
    • 7.5.1.Market size and forecast, by region
    • 7.5.2.Market share analysis, by country
  • 7.6.Others
    • 7.6.1.Market size and forecast, by region
    • 7.6.2.Market share analysis, by country

CHAPTER 8:IN VITRO DIAGNOSTICS MARKET, BY REGION

  • 8.1.Overview
    • 8.1.1.Market size and forecast
  • 8.2.North America
    • 8.2.1.Key market trends, growth factors, and opportunities
    • 8.2.2.Market size and forecast, by country
      • 8.2.2.1.U.S.
      • 8.2.2.1.1.U.S. in vitro diagnostics market, by product & service
      • 8.2.2.1.2.U.S. In vitro diagnostics market, by technique
      • 8.2.2.1.3.U.S. In vitro diagnostics market, by application
      • 8.2.2.1.4.U.S. In vitro diagnostics market, by end user
      • 8.2.2.2.Canada
      • 8.2.2.2.1.Canada iIn vitro diagnostics market, by product & service
      • 8.2.2.2.2.Canada In vitro diagnostics market, by technique
      • 8.2.2.2.3.Canada In vitro diagnostics market, by application
      • 8.2.2.2.4.Canada In vitro diagnostics market, by end user
      • 8.2.2.3.Mexico
      • 8.2.2.3.1.Mexico In vitro diagnostics market, by product & service
      • 8.2.2.3.2.Mexico In vitro diagnostics market, by technique
      • 8.2.2.3.3.Mexico In vitro diagnostics market, by application
      • 8.2.2.3.4.Mexico In vitro diagnostics market, by end user
    • 8.2.3.Market size and forecast, by product & service
    • 8.2.4.Market size and forecast, by technique
    • 8.2.5.Market size and forecast, by application
    • 8.2.6.Market size and forecast, by end user
  • 8.3.Europe
    • 8.3.1.Key market trends, growth factors, and opportunities
    • 8.3.2.Market size and forecast, by country
      • 8.3.2.1.Germany
      • 8.3.2.1.1.Germany In vitro diagnostics market, by product & service
      • 8.3.2.1.2.Germany In vitro diagnostics market, by technique
      • 8.3.2.1.3.Germany In vitro diagnostics market, by application
      • 8.3.2.1.4.Germany In vitro diagnostics market, by end user
      • 8.3.2.2.France
      • 8.3.2.2.1.France In vitro diagnostics market, by product & service
      • 8.3.2.2.2.France In vitro diagnostics market, by technique
      • 8.3.2.2.3.France In vitro diagnostics market, by application
      • 8.3.2.2.4.France In vitro diagnostics market, by end user
      • 8.3.2.3.UK
      • 8.3.2.3.1.UK In vitro diagnostics market, by product & service
      • 8.3.2.3.2.UK In vitro diagnostics market, by technique
      • 8.3.2.3.3.UK In vitro diagnostics market, by application
      • 8.3.2.3.4.UK In vitro diagnostics market, by end user
      • 8.3.2.4.Italy
      • 8.3.2.4.1.Italy In vitro diagnostics market, by product & service
      • 8.3.2.4.2.Italy In vitro diagnostics market, by technique
      • 8.3.2.4.3.Italy In vitro diagnostics market, by application
      • 8.3.2.4.4.Italy In vitro diagnostics market, by end user
      • 8.3.2.5.Spain
      • 8.3.2.5.1.Spain In vitro diagnostics market, by product & service
      • 8.3.2.5.2.Spain In vitro diagnostics market, by technique
      • 8.3.2.5.3.Spain In vitro diagnostics market, by application
      • 8.3.2.5.4.Spain In vitro diagnostics market, by end user
      • 8.3.2.6.Rest of Europe
      • 8.3.2.6.1.Rest of Europe In vitro diagnostics market, by product & service
      • 8.3.2.6.2.Rest of Europe In vitro diagnostics market, by technique
      • 8.3.2.6.3.Rest of Europe In vitro diagnostics market, by application
      • 8.3.2.6.4.Rest of Europe In vitro diagnostics market, by end user
    • 8.3.3.Market size and forecast, by product & service
    • 8.3.4.Market size and forecast, by technique
    • 8.3.5.Market size and forecast, by application
    • 8.3.6.Market size and forecast, by end user
  • 8.4.Asia-Pacific
    • 8.4.1.Key market trends, growth factors, and opportunities
    • 8.4.2.Market size and forecast, by country
      • 8.4.2.1.India
      • 8.4.2.1.1.India In vitro diagnostics market, by product & service
      • 8.4.2.1.2.India In vitro diagnostics market, by technique
      • 8.4.2.1.3.India In vitro diagnostics market, by application
      • 8.4.2.1.4.India In vitro diagnostics market, by end user
      • 8.4.2.2.China
      • 8.4.2.2.1.China In vitro diagnostics market, by product & service
      • 8.4.2.2.2.China In vitro diagnostics market, by technique
      • 8.4.2.2.3.China In vitro diagnostics market, by application
      • 8.4.2.2.4.China In vitro diagnostics market, by end user
      • 8.4.2.3.Japan
      • 8.4.2.3.1.Japan In vitro diagnostics market, by product & service
      • 8.4.2.3.2.Japan In vitro diagnostics market, by technique
      • 8.4.2.3.3.Japan In vitro diagnostics market, by application
      • 8.4.2.3.4.Japan In vitro diagnostics market, by end user
      • 8.4.2.4.Australia
      • 8.4.2.4.1.Australia In vitro diagnostics market, by product & service
      • 8.4.2.4.2.Australia In vitro diagnostics market, by technique
      • 8.4.2.4.3.Australia In vitro diagnostics market, by application
      • 8.4.2.4.4.Australia In vitro diagnostics market, by end user
      • 8.4.2.5.South Korea
      • 8.4.2.5.1.South Korea In vitro diagnostics market, by product & service
      • 8.4.2.5.2.South Korea In vitro diagnostics market, by technique
      • 8.4.2.5.3.South Korea In vitro diagnostics market, by application
      • 8.4.2.5.4.South Korea In vitro diagnostics market, by end user
      • 8.4.2.6.Rest of Asia-Pacific
      • 8.4.2.6.1.Rest of Asia-Pacific In vitro diagnostics market, by product & service
      • 8.4.2.6.2.Rest of Asia-Pacific In vitro diagnostics market, by technique
      • 8.4.2.6.3.Rest of Asia-Pacific In vitro diagnostics market, by application
      • 8.4.2.6.4.Rest of Asia-Pacific In vitro diagnostics market, by end user
    • 8.4.3.Market size and forecast, by product & service
    • 8.4.4.Market size and forecast, by technique
    • 8.4.5.Market size and forecast, by application
    • 8.4.6.Market size and forecast, by end user
  • 8.5.LAMEA
    • 8.5.1.Key market trends, growth factors, and opportunities
    • 8.5.2.Market size and forecast, by country
      • 8.5.2.1.Brazil
      • 8.5.2.1.1.Brazil In vitro diagnostics market, by product & service
      • 8.5.2.1.2.Brazil In vitro diagnostics market, by technique
      • 8.5.2.1.3.Brazil In vitro diagnostics market, by application
      • 8.5.2.1.4.Brazil In vitro diagnostics market, by end user
      • 8.5.2.2.Saudi Arabia
      • 8.5.2.2.1.Saudi Arabia In vitro diagnostics market, by product & service
      • 8.5.2.2.2.Saudi Arabia In vitro diagnostics market, by technique
      • 8.5.2.2.3.Saudi Arabia In vitro diagnostics market, by application
      • 8.5.2.2.4.Saudi Arabia In vitro diagnostics market, by end user
      • 8.5.2.3.South Africa
      • 8.5.2.3.1.South Africa In vitro diagnostics market, by product & service
      • 8.5.2.3.2.South Africa In vitro diagnostics market, by technique
      • 8.5.2.3.3.South Africa In vitro diagnostics market, by application
      • 8.5.2.3.4.South Africa In vitro diagnostics market, by end user
      • 8.5.2.4.Rest of LAMEA
      • 8.5.2.4.1.Rest of LAMEA In vitro diagnostics market, by product & service
      • 8.5.2.4.2.Rest of LAMEA In vitro diagnostics market, by technique
      • 8.5.2.4.3.Rest of LAMEA In vitro diagnostics market, by application
      • 8.5.2.4.4.Rest of LAMEA In vitro diagnostics market, by end user
    • 8.5.3.Market size and forecast, by product & service
    • 8.5.4.Market size and forecast, by technique
    • 8.5.5.Market size and forecast, by application
    • 8.5.6.Market size and forecast, by end user

CHAPTER 9:COMPANY PROFILES

  • 9.1.ABBOTT LABORATORIES
    • 9.1.1.Company overview
    • 9.1.2.Company snapshot
    • 9.1.3.Operating business segments
    • 9.1.4.Product and service portfolio
    • 9.1.5.Business performance
    • 9.1.6.Key strategic moves and developments
  • 9.2.BECTON, DICKINSON AND COMPANY
    • 9.2.1.Company overview
    • 9.2.2.Company snapshot
    • 9.2.3.Operating business segments
    • 9.2.4.Product and service portfolio
    • 9.2.5.Business performance
    • 9.2.6.Key strategic moves and developments
  • 9.3.BIOMERIEUX SA
    • 9.3.1.Company overview
    • 9.3.2.Company snapshot
    • 9.3.3.Operating business segments
    • 9.3.4.Product and service portfolio
    • 9.3.5.Business performance
    • 9.3.6.Key strategic moves and developments
  • 9.4.BIO-RAD LABORATORIES, INC.
    • 9.4.1.Company overview
    • 9.4.2.Company snapshot
    • 9.4.3.Operating business segments
    • 9.4.4.Product and service portfolio
    • 9.4.5.Business performance
    • 9.4.6.Key strategic moves and developments
  • 9.5.DANAHER CORPORATION (BECKMAN COULTER, INC.)
    • 9.5.1.Company overview
    • 9.5.2.Company snapshot
    • 9.5.3.Operating business segments
    • 9.5.4.Product and service portfolio
    • 9.5.5.Business performance
    • 9.5.6.Key strategic moves and developments
  • 9.6.F. HOFFMANN-LA ROCHE AG.
    • 9.6.1.Company snapshot
    • 9.6.2.Operating business segments
    • 9.6.3.Product and service portfolio
    • 9.6.4.Business performance
    • 9.6.5.Key strategic moves and developments
  • 9.7.QIAGEN N.V.
    • 9.7.1.Company overview
    • 9.7.2.Company snapshot
    • 9.7.3.Operating business segments
    • 9.7.4.Product and service portfolio
    • 9.7.5.Business performance
    • 9.7.6.Key strategic moves and developments
  • 9.8.SIEMENS AG (SIEMENS HEALTHINEERS)
    • 9.8.1.Company overview
    • 9.8.2.Company snapshot
    • 9.8.3.Operating business segments
    • 9.8.4.Product portfolio
    • 9.8.5.Business performance
    • 9.8.6.Key strategic moves and developments
  • 9.9.SYSMEX CORPORATION
    • 9.9.1.Company overview
    • 9.9.2.Company snapshot
    • 9.9.3.Operating business segments
    • 9.9.4.Product and service portfolio
    • 9.9.5.Business performance
  • 9.10.THERMO FISHER SCIENTIFIC, INC.
    • 9.10.1.Company overview
    • 9.10.2.Company snapshot
    • 9.10.3.Operating business segments
    • 9.10.4.Product and service portfolio
    • 9.10.5.Business performance
    • 9.10.6.Key strategic moves and developments

LIST OF TABLES

  • TABLE 01.IN VITRO DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2019-2027 ($MILLION)
  • TABLE 02.IN VITRO DIAGNOSTICS MARKET FOR REAGENTS, BY REGION, 2019-2027 ($MILLION)
  • TABLE 03.IN VITRO DIAGNOSTICS MARKET FOR INSTRUMENTS, BY REGION, 2019-2027 ($MILLION)
  • TABLE 04.IN VITRO DIAGNOSTICS MARKET FOR SOFTWARE & SERVICES, BY REGION, 2019-2027 ($MILLION)
  • TABLE 05.IN VITRO DIAGNOSTICS MARKET, BY TECHNIQUE, 2019-2027 ($MILLION)
  • TABLE 06.IN VITRO DIAGNOSTICS MARKET FOR IMMUNODIAGNOSTICS, BY TYPE, 2019-2027 ($MILLION)
  • TABLE 07.IN VITRO DIAGNOSTICS MARKET FOR ELISA, BY TYPE 2019-2027 ($MILLION)
  • TABLE 08.IN VITRO DIAGNOSTICS MARKET FOR IMMUNODIAGNOSTICS, BY REGION, 2019-2027 ($MILLION)
  • TABLE 09.IN VITRO DIAGNOSTICS MARKET FOR HEMATOLOGY, BY REGION, 2019-2027 ($MILLION)
  • TABLE 10.MOLECULAR DIAGNOSTICS MARKET, BY TYPE, 2019-2027 ($MILLION)
  • TABLE 11.IN VITRO DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS, BY REGION, 2019-2027 ($MILLION)
  • TABLE 12.IN VITRO DIAGNOSTICS MARKET FOR TISSUE DIAGNOSTICS, BY REGION, 2019-2027 ($MILLION)
  • TABLE 13.CLINICAL CHEMISTRY MARKET, BY TYPE, 2019-2027 ($MILLION)
  • TABLE 14.IN VITRO DIAGNOSTICS MARKET FOR CLINICAL CHEMISTRY, BY REGION, 2019-2027 ($MILLION)
  • TABLE 15.IN VITRO DIAGNOSTICS MARKET FOR OTHERS, BY REGION, 2019-2027 ($MILLION)
  • TABLE 16.IN VITRO DIAGNOSTICS MARKET, BY APPLICATION, 2019-2027 ($MILLION)
  • TABLE 17.IN VITRO DIAGNOSTICS MARKET FOR INFECTIOUS DISEASES, BY REGION,2019-2027 ($MILLION)
  • TABLE 18.IN VITRO DIAGNOSTICS MARKET FOR CANCER, BY REGION, 2019-2027 ($MILLION)
  • TABLE 19.IN VITRO DIAGNOSTICS MARKET FOR CARDIAC DISEASES, BY REGION, 2019-2027 ($MILLION)
  • TABLE 20.IN VITRO DIAGNOSTICS MARKET FOR IMMUNE SYSTEM DISORDERS, BY REGION, 2019-2027 ($MILLION)
  • TABLE 21.IN VITRO DIAGNOSTICS MARKET FOR NEPHROLOGICAL DISEASES, BY REGION, 2019-2027 ($MILLION)
  • TABLE 22.IN VITRO DIAGNOSTICS MARKET FOR GASTROINTESTINAL DISEASES, BY REGION, 2019-2027 ($MILLION)
  • TABLE 23.IN VITRO DIAGNOSTICS MARKET FOR OTHER, BY REGION, 2019-2027 ($MILLION)
  • TABLE 24.IN VITRO DIAGNOSTICS MARKET, BY END USER, 2019-2027 ($MILLION)
  • TABLE 25.IN VITRO DIAGNOSTICS MARKET FOR STANDALONE LABORATORIES, BY REGION, 2019-2027 ($MILLION)
  • TABLE 26.IN VITRO DIAGNOSTICS MARKET FOR HOSPITALS, BY REGION, 2019-2027 ($MILLION)
  • TABLE 27.IN VITRO DIAGNOSTICS MARKET FOR ACADEMIC AND MEDICAL SCHOOL, BY REGION, 2019-2027 ($MILLION)
  • TABLE 28.IN VITRO DIAGNOSTICS MARKET FOR POINT-OF-CARE TESTING, BY REGION, 2019-2027 ($MILLION)
  • TABLE 29.IN VITRO DIAGNOSTICS MARKET FOR OTHERS, BY REGION, 2019-2027 ($MILLION)
  • TABLE 30.IN VITRO DIAGNOSTICS MARKET REVENUE, BY REGION, 2019-2027 ($MILLION)
  • TABLE 31.NORTH AMERICA IN VITRO DIAGNOSTICS MARKET, BY COUNTRY, 2019-2027 ($MILLION)
  • TABLE 32.U.S. IN VITRO DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2019-2027
  • TABLE 33.U.S. IN VITRO DIAGNOSTICS MARKET, BY TECHNIQUE, 2019-2027
  • TABLE 34.U.S. IN VITRO DIAGNOSTICS MARKET, BY APPLICATION, 2019-2027
  • TABLE 35.U.S. IN VITRO DIAGNOSTICS MARKET, BY END USER, 2019-2027
  • TABLE 36.CANADA IN VITRO DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2019-2027
  • TABLE 37.CANADA IN VITRO DIAGNOSTICS MARKET, BY TECHNIQUE, 2019-2027
  • TABLE 38.CANADA IN VITRO DIAGNOSTICS MARKET, BY APPLICATION, 2019-2027
  • TABLE 39.CANADA IN VITRO DIAGNOSTICS MARKET, BY END USER, 2019-2027
  • TABLE 40.MEXICO IN VITRO DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2019-2027
  • TABLE 41.MEXICO IN VITRO DIAGNOSTICS MARKET, BY TECHNIQUE, 2019-2027
  • TABLE 42.MEXICO IN VITRO DIAGNOSTICS MARKET, BY APPLICATION, 2019-2027
  • TABLE 43.MEXICO IN VITRO DIAGNOSTICS MARKET, BY END USER, 2019-2027
  • TABLE 44.NORTH AMERICA IN VITRO DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2019-2027 ($MILLION)
  • TABLE 45.NORTH AMERICA IN VITRO DIAGNOSTICS MARKET, BY TECHNIQUE, 2019-2027 ($MILLION)
  • TABLE 46.NORTH AMERICA IN VITRO DIAGNOSTICS MARKET, BY APPLICATION, 2019-2027 ($MILLION)
  • TABLE 47.NORTH AMERICA IN VITRO DIAGNOSTICS MARKET, BY END USER, 2019-2027 ($MILLION)
  • TABLE 48.EUROPE IN VITRO DIAGNOSTICS MARKET, BY COUNTRY, 2019-2027 ($MILLION)
  • TABLE 49.GERMANY IN VITRO DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2019-2027
  • TABLE 50.GERMANY IN VITRO DIAGNOSTICS MARKET, BY TECHNIQUE, 2019-2027
  • TABLE 51.GERMANY IN VITRO DIAGNOSTICS MARKET, BY APPLICATION, 2019-2027
  • TABLE 52.GERMANY IN VITRO DIAGNOSTICS MARKET, BY END USER, 2019-2027
  • TABLE 53.FRANCE IN VITRO DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2019-2027
  • TABLE 54.FRANCE IN VITRO DIAGNOSTICS MARKET, BY TECHNIQUE, 2019-2027
  • TABLE 55.FRANCE IN VITRO DIAGNOSTICS MARKET, BY APPLICATION, 2019-2027
  • TABLE 56.FRANCE IN VITRO DIAGNOSTICS MARKET, BY END USER, 2019-2027
  • TABLE 57.UK IN VITRO DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2019-2027
  • TABLE 58.UK IN VITRO DIAGNOSTICS MARKET, BY TECHNIQUE, 2019-2027
  • TABLE 59.UK IN VITRO DIAGNOSTICS MARKET, BY APPLICATION, 2019-2027
  • TABLE 60.UK IN VITRO DIAGNOSTICS MARKET, BY END USER, 2019-2027
  • TABLE 61.ITALY IN VITRO DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2019-2027
  • TABLE 62.ITALY IN VITRO DIAGNOSTICS MARKET, BY TECHNIQUE, 2019-2027
  • TABLE 63.ITALY IN VITRO DIAGNOSTICS MARKET, BY APPLICATION, 2019-2027
  • TABLE 64.ITALY IN VITRO DIAGNOSTICS MARKET, BY END USER, 2019-2027
  • TABLE 65.SPAIN IN VITRO DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2019-2027
  • TABLE 66.SPAIN IN VITRO DIAGNOSTICS MARKET, BY TECHNIQUE, 2019-2027
  • TABLE 67.SPAIN IN VITRO DIAGNOSTICS MARKET, BY APPLICATION, 2019-2027
  • TABLE 68.SPAIN IN VITRO DIAGNOSTICS MARKET, BY END USER, 2019-2027
  • TABLE 69.REST OF EUROPE IN VITRO DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2019-2027
  • TABLE 70.REST OF EUROPE IN VITRO DIAGNOSTICS MARKET, BY TECHNIQUE, 2019-2027
  • TABLE 71.REST OF EUROPE IN VITRO DIAGNOSTICS MARKET, BY APPLICATION, 2019-2027
  • TABLE 72.REST OF EUROPE IN VITRO DIAGNOSTICS MARKET, BY END USER, 2019-2027
  • TABLE 73.EUROPE IN VITRO DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2019-2027 ($MILLION)
  • TABLE 74.EUROPE IN VITRO DIAGNOSTICS MARKET, BY TECHNIQUE, 2019-2027 ($MILLION)
  • TABLE 75.EUROPE IN VITRO DIAGNOSTICS MARKET, BY APPLICATION, 2019-2027 ($MILLION)
  • TABLE 76.EUROPE IN VITRO DIAGNOSTICS MARKET, BY END USER, 2019-2027 ($MILLION)
  • TABLE 77.ASIA-PACIFIC IN VITRO DIAGNOSTICS MARKET, BY COUNTRY, 2019-2027 ($MILLION)
  • TABLE 78.INDIA IN VITRO DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2019-2027
  • TABLE 79.INDIA IN VITRO DIAGNOSTICS MARKET, BY TECHNIQUE, 2019-2027
  • TABLE 80.INDIA IN VITRO DIAGNOSTICS MARKET, BY APPLICATION, 2019-2027
  • TABLE 81.INDIA IN VITRO DIAGNOSTICS MARKET, BY END USER, 2019-2027
  • TABLE 82.CHINA IN VITRO DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2019-2027
  • TABLE 83.CHINA IN VITRO DIAGNOSTICS MARKET, BY TECHNIQUE, 2019-2027
  • TABLE 84.CHINA IN VITRO DIAGNOSTICS MARKET, BY APPLICATION, 2019-2027
  • TABLE 85.CHINA IN VITRO DIAGNOSTICS MARKET, BY END USER, 2019-2027
  • TABLE 86.JAPAN IN VITRO DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2019-2027
  • TABLE 87.JAPAN IN VITRO DIAGNOSTICS MARKET, BY TECHNIQUE, 2019-2027
  • TABLE 88.JAPAN IN VITRO DIAGNOSTICS MARKET, BY APPLICATION, 2019-2027
  • TABLE 89.JAPAN IN VITRO DIAGNOSTICS MARKET, BY END USER, 2019-2027
  • TABLE 90.AUSTRALIA IN VITRO DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2019-2027
  • TABLE 91.AUSTRALIA IN VITRO DIAGNOSTICS MARKET, BY TECHNIQUE, 2019-2027
  • TABLE 92.AUSTRALIA IN VITRO DIAGNOSTICS MARKET, BY APPLICATION, 2019-2027
  • TABLE 93.AUSTRALIA IN VITRO DIAGNOSTICS MARKET, BY END USER, 2019-2027
  • TABLE 94.SOUTH KOREA IN VITRO DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2019-2027
  • TABLE 95.SOUTH KOREA IN VITRO DIAGNOSTICS MARKET, BY TECHNIQUE, 2019-2027
  • TABLE 96.SOUTH KOREA IN VITRO DIAGNOSTICS MARKET, BY APPLICATION, 2019-2027
  • TABLE 97.SOUTH KOREA IN VITRO DIAGNOSTICS MARKET, BY END USER, 2019-2027
  • TABLE 98.REST OF ASIA-PACIFIC IN VITRO DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2019-2027
  • TABLE 99.REST OF ASIA-PACIFIC IN VITRO DIAGNOSTICS MARKET, BY TECHNIQUE, 2019-2027
  • TABLE 100.REST OF ASIA-PACIFIC IN VITRO DIAGNOSTICS MARKET, BY APPLICATION, 2019-2027
  • TABLE 101.REST OF ASIA-PACIFIC IN VITRO DIAGNOSTICS MARKET, BY END USER, 2019-2027
  • TABLE 102.ASIA-PACIFIC IN VITRO DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2019-2027 ($MILLION)
  • TABLE 103.ASIA-PACIFIC IN VITRO DIAGNOSTICS MARKET, BY TECHNIQUE, 2019-2027 ($MILLION)
  • TABLE 104.ASIA-PACIFIC IN VITRO DIAGNOSTICS MARKET, BY APPLICATION, 2019-2027 ($MILLION)
  • TABLE 105.ASIA-PACIFIC IN VITRO DIAGNOSTICS MARKET, BY END USER, 2019-2027 ($MILLION)
  • TABLE 106.LAMEA IN VITRO DIAGNOSTICS MARKET, BY COUNTRY, 2019-2027 ($MILLION)
  • TABLE 107.BRAZIL IN VITRO DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2019-2027
  • TABLE 108.BRAZIL IN VITRO DIAGNOSTICS MARKET, BY TECHNIQUE, 2019-2027
  • TABLE 109.BRAZIL IN VITRO DIAGNOSTICS MARKET, BY APPLICATION, 2019-2027
  • TABLE 110.BRAZIL IN VITRO DIAGNOSTICS MARKET, BY END USER, 2019-2027
  • TABLE 111.SAUDI ARABIA IN VITRO DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2019-2027
  • TABLE 112.SAUDI ARABIA IN VITRO DIAGNOSTICS MARKET, BY TECHNIQUE, 2019-2027
  • TABLE 113.SAUDI ARABIA IN VITRO DIAGNOSTICS MARKET, BY APPLICATION, 2019-2027
  • TABLE 114.SAUDI ARABIA IN VITRO DIAGNOSTICS MARKET, BY END USER, 2019-2027
  • TABLE 115.SOUTH AFRICA IN VITRO DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2019-2027
  • TABLE 116.SOUTH AFRICA IN VITRO DIAGNOSTICS MARKET, BY TECHNIQUE, 2019-2027
  • TABLE 117.SOUTH AFRICA IN VITRO DIAGNOSTICS MARKET, BY APPLICATION, 2019-2027
  • TABLE 118.SOUTH AFRICA IN VITRO DIAGNOSTICS MARKET, BY END USER, 2019-2027
  • TABLE 119.REST OF LAMEA IN VITRO DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2019-2027
  • TABLE 120.REST OF LAMEA IN VITRO DIAGNOSTICS MARKET, BY TECHNIQUE, 2019-2027
  • TABLE 121.REST OF LAMEA IN VITRO DIAGNOSTICS MARKET, BY APPLICATION, 2019-2027
  • TABLE 122.REST OF LAMEA IN VITRO DIAGNOSTICS MARKET, BY END USER, 2019-2027
  • TABLE 123.LAMEA IN VITRO DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2019-2027 ($MILLION)
  • TABLE 124.LAMEA IN VITRO DIAGNOSTICS MARKET, BY TECHNIQUE, 2019-2027 ($MILLION)
  • TABLE 125.LAMEA IN VITRO DIAGNOSTICS MARKET, BY APPLICATION, 2019-2027 ($MILLION)
  • TABLE 126.LAMEA IN VITRO DIAGNOSTICS MARKET, BY END USER, 2019-2027 ($MILLION)
  • TABLE 127.ABBOTT: COMPANY SNAPSHOT
  • TABLE 128.ABBOTT: OPERATING SEGMENTS
  • TABLE 129.ABBOTT: PRODUCT AND SERVICE PORTFOLIO
  • TABLE 130.BD : COMPANY SNAPSHOT
  • TABLE 131.BD : OPERATING SEGMENTS
  • TABLE 132.BD: PRODUCT AND SERVICE PORTFOLIO
  • TABLE 133.BIOMERIEUX: COMPANY SNAPSHOT
  • TABLE 134.BIOMERIEUX: OPERATING SEGMENTS
  • TABLE 135.BIOMERIEUX: PRODUCT AND SERVICE PORTFOLIO
  • TABLE 136.BIO-RAD: COMPANY SNAPSHOT
  • TABLE 137.BIO-RAD: OPERATING SEGMENTS
  • TABLE 138.BIO-RAD: PRODUCT AND SERVICE PORTFOLIO
  • TABLE 139.DANAHER: COMPANY SNAPSHOT
  • TABLE 140.DANAHER: OPERATING SEGMENTS
  • TABLE 141.DANAHER: PRODUCT AND SERVICE PORTFOLIO
  • TABLE 142.ROCHE: COMPANY SNAPSHOT
  • TABLE 143.ROCHE: OPERATING SEGMENTS
  • TABLE 144.ROCHE: PRODUCT AND SERVICE PORTFOLIO
  • TABLE 145.QIAGEN: COMPANY SNAPSHOT
  • TABLE 146.QIAGEN: OPERATING SEGMENTS
  • TABLE 147.QIAGEN: PRODUCT AND SERVICE PORTFOLIO
  • TABLE 148.SIEMENS: COMPANY SNAPSHOT
  • TABLE 149.SIEMENS: OPERATING SEGMENTS
  • TABLE 150.SIEMENS: PRODUCT PORTFOLIO
  • TABLE 151.SYSMEX: COMPANY SNAPSHOT
  • TABLE 152.SYSMEX: OPERATING SEGMENTS
  • TABLE 153.SYSMEX: PRODUCT AND SERVICE PORTFOLIO
  • TABLE 154.THERMO FISHER: COMPANY SNAPSHOT
  • TABLE 155.THERMO FISHER: OPERATING SEGMENTS
  • TABLE 156.THERMO FISHER SCIENTIFIC: PRODUCT AND SERVICE PORTFOLIO

LIST OF FIGURES

  • FIGURE 01.IN-VITRO DIAGNOSTICS MARKET SEGMENTATION
  • FIGURE 02.TECHNIQUE MARKET SUB-SEGMENTATION
  • FIGURE 03.TOP INVESTMENT POCKETS
  • FIGURE 04.TOP WINNING STRATEGIES, 2017-2020
  • FIGURE 05.TOP WINNING STRATEGIES: NATURE AND TYPE, 2017-2020
  • FIGURE 06.TOP WINNING STRATEGIES: BY YEAR, 2017-2020
  • FIGURE 07.TOP PLAYER POSITIONING, 2019
  • FIGURE 08.BARGANING POWER OF BUYERS
  • FIGURE 09.BARGANING POWER OF SUPPLIERS
  • FIGURE 10.THREAT OF SUBSTITUTIONS
  • FIGURE 11.THREAT OF NEW ENTRANTS
  • FIGURE 12.MODERATE COMPETITIVE RIVALRY
  • FIGURE 13.IMPACT ANALYSIS, IN-VITRO DIAGNOSTICS MARKET
  • FIGURE 14.COMPARATIVE ANALYSIS OF IN VITRO DIAGNOSTICS MARKET FOR REAGENTS, BY COUNTRY, 2019 & 2027
  • FIGURE 15.COMPARATIVE ANALYSIS OF IN VITRO DIAGNOSTICS MARKET FOR INSTRUMENTS, BY COUNTRY, 2019 & 2027
  • FIGURE 16.COMPARATIVE ANALYSIS OF IN VITRO DIAGNOSTICS MARKET FOR SOFTWARE & SERVICES, BY COUNTRY, 2019 & 2027
  • FIGURE 17.IMMUNODIAGNOSTICS MARKET FOR ENZYME LINKED IMMUNOSORBENT ASSAY, 2019-2027 ($MILLION)
  • FIGURE 18.IMMUNODIAGNOSTICS MARKET FOR RAPID TESTS, 2019-2027 ($MILLION)
  • FIGURE 19.IMMUNODIAGNOSTICS MARKET FOR ENZYME-LINKED IMMUNOSPOT (ELISPOT), 2019-2027 ($MILLION)
  • FIGURE 20.IMMUNODIAGNOSTICS MARKET FOR RADIOIMMUNOASSAY (RIA), 2019-2027 ($MILLION)
  • FIGURE 21.IMMUNODIAGNOSTICS MARKET FOR WESTERN BLOT, 2019-2027 ($MILLION)
  • FIGURE 22.COMPARATIVE ANALYSIS OF IN VITRO DIAGNOSTICS MARKET FOR IMMUNODIAGNOSTICS, BY COUNTRY, 2019 & 2027
  • FIGURE 23.COMPARATIVE ANALYSIS OF IN VITRO DIAGNOSTICS MARKET FOR HEMATOLOGY, BY COUNTRY, 2019 & 2027
  • FIGURE 24.MOLECULAR DIAGNOSTICS MARKET FOR POLYMERIZE CHAIN REACTION (PCR), 2019-2027 ($MILLION)
  • FIGURE 25.MOLECULAR DIAGNOSTICS MARKET FOR ISOTHERMAL NUCLEIC ACID AMPLIFICATION TECHNOLOGY (INAAT), 2019-2027 ($MILLION)
  • FIGURE 26.MOLECULAR DIAGNOSTICS MARKET FOR HYBRIDIZATION, 2019-2027 ($MILLION)
  • FIGURE 27.MOLECULAR DIAGNOSTICS MARKET FOR DNA DIAGNOSTICS, 2019-2027 ($MILLION)
  • FIGURE 28.MOLECULAR DIAGNOSTICS MARKET FOR MICROARRAY, 2019-2027 ($MILLION)
  • FIGURE 29.MOLECULAR DIAGNOSTICS MARKET FOR OTHERS, 2019-2027 ($MILLION)
  • FIGURE 30.COMPARATIVE ANALYSIS OF IN VITRO DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS, BY COUNTRY, 2019 & 2027
  • FIGURE 31.COMPARATIVE ANALYSIS OF IN VITRO DIAGNOSTICS MARKET FOR TISSUE DIAGNOSTICS, BY COUNTRY, 2019 & 2027
  • FIGURE 32.CLINICAL CHEMISTRY MARKET FOR BASIC METABOLIC PANEL, 2019-2027 ($MILLION)
  • FIGURE 33.CLINICAL CHEMISTRY MARKET FOR LIVER PANEL, 2019-2027 ($MILLION)
  • FIGURE 34.CLINICAL CHEMISTRY MARKET FOR RENAL PROFILE, 2019-2027 ($MILLION)
  • FIGURE 35.CLINICAL CHEMISTRY MARKET FOR LIPID PROFILE, 2019-2027 ($MILLION)
  • FIGURE 36.CLINICAL CHEMISTRY MARKET FOR THYROID FUNCTION PANEL, 2019-2027 ($MILLION)
  • FIGURE 37.CLINICAL CHEMISTRY MARKET FOR ELECTROLYTE PANEL, 2019-2027 ($MILLION)
  • FIGURE 38.CLINICAL CHEMISTRY MARKET FOR SPECIALTY CHEMICALS, 2019-2027 ($MILLION)
  • FIGURE 39.COMPARATIVE ANALYSIS OF IN VITRO DIAGNOSTICS MARKET FOR CLINICAL CHEMISTRY, BY COUNTRY, 2019 & 2027
  • FIGURE 40.COMPARATIVE ANALYSIS OF IN VITRO DIAGNOSTICS MARKET FOR OTHERS IVD TECHNIQUES, BY COUNTRY, 2019 & 2027
  • FIGURE 41.COMPARATIVE ANALYSIS OF IN VITRO DIAGNOSTICS MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2019 & 2027
  • FIGURE 42.COMPARATIVE ANALYSIS OF IN VITRO DIAGNOSTICS MARKET FOR CANCER, BY COUNTRY, 2019 & 2027
  • FIGURE 43.COMPARATIVE ANALYSIS OF IN VITRO DIAGNOSTICS MARKET FOR CARDIAC DISEASES, BY COUNTRY, 2019 & 2027
  • FIGURE 44.COMPARATIVE ANALYSIS OF IN VITRO DIAGNOSTICS MARKET FOR IMMUNE SYSTEM DISORDERS, BY COUNTRY, 2019 & 2027
  • FIGURE 45.COMPARATIVE ANALYSIS OF IN VITRO DIAGNOSTICS MARKET FOR NEPHROLOGICAL DISEASES, BY COUNTRY, 2019 & 2027
  • FIGURE 46.COMPARATIVE ANALYSIS OF IN VITRO DIAGNOSTICS MARKET FOR GASTROINTESTINAL DISEASES, BY COUNTRY, 2019 & 2027
  • FIGURE 47.COMPARATIVE ANALYSIS OF IN VITRO DIAGNOSTICS MARKET FOR OTHER, BY COUNTRY, 2019 & 2027
  • FIGURE 48.COMPARATIVE ANALYSIS OF IN VITRO DIAGNOSTICS MARKET FOR STANDALONE LABORATORIES, BY COUNTRY, 2019 & 2027
  • FIGURE 49.COMPARATIVE ANALYSIS OF IN VITRO DIAGNOSTICS MARKET FOR HOSPITALS, BY COUNTRY, 2019 & 2027
  • FIGURE 50.COMPARATIVE ANALYSIS OF IN VITRO DIAGNOSTICS MARKET FOR ACADEMIC AND MEDICAL SCHOOLS, BY COUNTRY, 2019 & 2027
  • FIGURE 51.COMPARATIVE ANALYSIS OF IN VITRO DIAGNOSTICS MARKET FOR POINT-OF-CARE TESTING, BY COUNTRY, 2019 & 2027
  • FIGURE 52.COMPARATIVE ANALYSIS OF IN VITRO DIAGNOSTICS MARKET FOR OTHERS, BY COUNTRY, 2019 & 2027
  • FIGURE 53.U.S. IN-VITRO DIAGNOSTICS MARKET, 2019-2027 ($MILLION)
  • FIGURE 54.CANADA IN-VITRO DIAGNOSTICS MARKET, 2019-2027 ($MILLION)
  • FIGURE 55.MEXICO IN-VITRO DIAGNOSTICS MARKET, 2019-2027 ($MILLION)
  • FIGURE 56.EUROPEAN GERIATRIC POPULATION (ABOVE 65 YEARS), 2017
  • FIGURE 57.GERMANY IN-VITRO DIAGNOSTICS MARKET, 2019-2027 ($MILLION)
  • FIGURE 58.FRANCE IN-VITRO DIAGNOSTICS MARKET, 2019-2027 ($MILLION)
  • FIGURE 59.UK. IN-VITRO DIAGNOSTICS MARKET, 2019-2027 ($MILLION)
  • FIGURE 60.ITALY IN-VITRO DIAGNOSTICS MARKET, 2019-2027 ($MILLION)
  • FIGURE 61.SPAIN IN-VITRO DIAGNOSTICS MARKET, 2019-2027 ($MILLION)
  • FIGURE 62.REST OF EUROPE IN-VITRO DIAGNOSTICS MARKET, 2019-2027 ($MILLION)
  • FIGURE 63.INDIA IN-VITRO DIAGNOSTICS MARKET, 2019-2027 ($MILLION)
  • FIGURE 64.CHINA IN-VITRO DIAGNOSTICS MARKET, 2019-2027 ($MILLION)
  • FIGURE 65.JAPAN IN-VITRO DIAGNOSTICS MARKET, 2019-2027 ($MILLION)
  • FIGURE 66.AUSTRALIA IN-VITRO DIAGNOSTICS MARKET, 2019-2027 ($MILLION)
  • FIGURE 67.SOUTH KOREA IN-VITRO DIAGNOSTICS MARKET, 2019-2027 ($MILLION)
  • FIGURE 68.REST OF ASIA-PACIFIC IN-VITRO DIAGNOSTICS MARKET, 2019-2027 ($MILLION)
  • FIGURE 69.BRAZIL IN-VITRO DIAGNOSTICS MARKET, 2019-2027 ($MILLION)
  • FIGURE 70.SAUDI ARABIA IN-VITRO DIAGNOSTICS MARKET, 2019-2027 ($MILLION)
  • FIGURE 71.SOUTH AFRICA IN-VITRO DIAGNOSTICS MARKET, 2019-2027 ($MILLION)
  • FIGURE 72.REST OF LAMEA IN-VITRO DIAGNOSTICS MARKET, 2019-2027 ($MILLION)
  • FIGURE 73.ABBOTT: NET SALES, 2017-2019 ($MILLION)
  • FIGURE 74.ABBOTT: NET SALES SHARE, BY OPERATING SEGMENT, 2019 (%)
  • FIGURE 75.ABBOTT: NET SALES SHARE, BY REGION, 2019 (%)
  • FIGURE 76.BD: REVENUE, 2017-2019 ($MILLION)
  • FIGURE 77.BD: REVENUE SHARE BY SEGMENT, 2019 (%)
  • FIGURE 78.BD: REVENUE SHARE BY REGION, 2019 (%)
  • FIGURE 79.BIOMERIEUX: NET SALES, 2016-2018 ($MILLION)
  • FIGURE 80.BIOMERIEUX: REVENUE SHARE BY SEGMENT, 2018 (%)
  • FIGURE 81.BIOMERIEUX: REVENUE SHARE BY REGION, 2018 (%)
  • FIGURE 82.BIO-RAD: NET SALES, 2017-2019 ($MILLION)
  • FIGURE 83.BIO-RAD: REVENUE SHARE BY SEGMENT, 2019 (%)
  • FIGURE 84.BIO-RAD: REVENUE SHARE BY REGION, 2019 (%)
  • FIGURE 85.DANAHER: NET SALES, 2017-2019 ($MILLION)
  • FIGURE 86.DANAHER: REVENUE SHARE BY SEGMENT, 2019 (%)
  • FIGURE 87.DANAHER: REVENUE SHARE BY REGION, 2019 (%)
  • FIGURE 88.ROCHE: NET SALES, 2017-2019 ($MILLION)
  • FIGURE 89.ROCHE: REVENUE SHARE BY SEGMENT, 2019 (%)
  • FIGURE 90.QIAGEN: NET SALES, 2017-2019 ($MILLION)
  • FIGURE 91.QIAGEN: REVENUE SHARE BY PRODUCT AND SERVICE, 2019 (%)
  • FIGURE 92.QIAGEN: REVENUE SHARE BY REGION, 2019 (%)
  • FIGURE 93.NET SALES, 2017-2019 ($MILLION)
  • FIGURE 94.SIEMENS: REVENUE SHARE, BY SEGMENT, 2019 (%)
  • FIGURE 95.SIEMENS: REVENUE SHARE, BY REGION, 2019 (%)
  • FIGURE 96.SYSMEX: REVENUE, 2017-2019 ($MILLION)
  • FIGURE 97.SYSMEX: REVENUE SHARE, BY SEGMENT, 2019 (%)
  • FIGURE 98.SYSMEX: REVENUE SHARE, BY REGION, 2019 (%)
  • FIGURE 99.THERMO FISHER SCIENTIFIC: REVENUE, 2016-2018 ($MILLION)
  • FIGURE 100.THERMO FISHER SCIENTIFIC: REVENUE SHARE, BY SEGMENT, 2018 (%)
  • FIGURE 101.THERMO FISHER SCIENTIFIC: REVENUE SHARE, BY REGION, 2018 (%)